journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology

journal
https://read.qxmd.com/read/31295041/ibrutinib-plus-venetoclax-in-relapsed-refractory-chronic-lymphocytic-leukemia-the-clarity-study
#1
Peter Hillmen, Andy C Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J Yates, Rebecca Bishop, Rebecca Boucher, Donald MacDonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G Gribben, Piers E M Patten, Stephen Devereux, Adrian Bloor, Christopher P Fox, Francesco Forconi, Talha Munir
PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We present the CLARITY trial that combined ibrutinib with venetoclax to eradicate detectable CLL with the intention of stopping therapy...
July 11, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31283410/how-long-is-this-going-to-take
#2
William S Shimp
No abstract text is available yet for this article.
July 8, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31283409/neoadjuvant-three-dimensional-conformal-radiotherapy-for-resectable-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-a-randomized-open-label-multicenter-controlled-study
#3
Xubiao Wei, Yabo Jiang, Xiuping Zhang, Shuang Feng, Bin Zhou, Xiaofei Ye, Hui Xing, Ying Xu, Jie Shi, Weixing Guo, Dong Zhou, Hui Zhang, Huichuan Sun, Cheng Huang, Congde Lu, Yaxin Zheng, Yan Meng, Bin Huang, Wenming Cong, Wan Yee Lau, Shuqun Cheng
PURPOSE: To compare the survival outcomes of neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy with hepatectomy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). PATIENTS AND METHODS: A randomized, multicenter controlled study was conducted from January 2016 to December 2017 in patients with resectable HCC and PVTT. Patients were randomly assigned to receive neoadjuvant RT followed by hepatectomy (n = 82) or hepatectomy alone (n = 82)...
July 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31283408/late-health-outcomes-after-contemporary-lymphome-malin-de-burkitt-therapy-for-mature-b-cell-non-hodgkin-lymphoma-a-report-from-the-childhood-cancer-survivor-study
#4
Matthew J Ehrhardt, Yan Chen, John T Sandlund, Elizabeth C Bluhm, Robert J Hayashi, Kerri Becktell, Wendy M Leisenring, Monika L Metzger, Kirsten K Ness, Kevin R Krull, Kevin C Oeffinger, Todd M Gibson, Mitchell S Cairo, Thomas G Gross, Leslie L Robison, Gregory T Armstrong, Yutaka Yasui, Melissa M Hudson, Daniel A Mulrooney
PURPOSE: The widely used, risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late effects remain understudied. We assessed late health outcomes after LMB treatment in the Childhood Cancer Survivor Study. PATIENTS AND METHODS: Multivariable regression models compared chronic health conditions, health status, and socioeconomic and neurocognitive outcomes between survivors of NHL treated with the LMB regimen (n = 126), survivors of NHL treated with non-LMB regimens (n = 444), and siblings (n = 1,029)...
July 8, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31283407/outcome-of-infants-younger-than-1-year-with-acute-lymphoblastic-leukemia-treated-with-the-interfant-06-protocol-results-from-an-international-phase-iii-randomized-study
#5
Rob Pieters, Paola De Lorenzo, Philip Ancliffe, Luis Alberto Aversa, Benoit Brethon, Andrea Biondi, Myriam Campbell, Gabriele Escherich, Alina Ferster, Rebecca A Gardner, Rishi Sury Kotecha, Birgitte Lausen, Chi Kong Li, Franco Locatelli, Andishe Attarbaschi, Christina Peters, Jeffrey E Rubnitz, Lewis B Silverman, Jan Stary, Tomasz Szczepanski, Ajay Vora, Martin Schrappe, Maria Grazia Valsecchi
PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A ( MLL ) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value. MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A -rearranged and older than 6 months with WBC count 300 × 109 /L or more or a poor prednisone response; and medium risk (MR): all other KMT2A -rearranged cases...
July 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31283406/patient-perceived-lack-of-choice-in-receipt-of-radioactive-iodine-for-treatment-of-differentiated-thyroid-cancer
#6
Lauren P Wallner, David Reyes-Gastelum, Ann S Hamilton, Kevin C Ward, Sarah T Hawley, Megan R Haymart
PURPOSE: For many patients with differentiated thyroid cancer, use of radioactive iodine (RAI) does not improve survival or reduce recurrence risk. Yet there is wide variation in RAI use, emphasizing the importance of understanding patient perspectives regarding RAI decision making. PATIENTS AND METHODS: All eligible patients diagnosed with thyroid cancer from 2014 to 2015 from the Georgia and Los Angeles SEER registries were surveyed (N = 2,632; response rate, 63%)...
July 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31268798/reply-to-s-sorscher
#7
Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M Goldberg, Monica M Bertagnolli, Charles David Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P Venook, Heinz-Josef Lenz, Omar Kabbarah
No abstract text is available yet for this article.
July 3, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31268797/molecular-markers-of-molecular-markers
#8
Steve Sorscher
No abstract text is available yet for this article.
July 3, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31265360/has-the-prophecy-of-ar-v7-been-fulfilled
#9
Bram De Laere, Piet Ost, Henrik Grönberg, Johan Lindberg
No abstract text is available yet for this article.
July 2, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31265359/dissecting-prognostic-from-predictive-utility-circulating-ar-v7-biomarker-testing-for-advanced-prostate-cancer
#10
Adam Sharp, Nuria Porta, Maryou B K Lambros, Jonathan C Welti, Alec Paschalis, Ganesh V Raj, Stephen P Plymate, Johann S de Bono
No abstract text is available yet for this article.
July 2, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31265358/predictive-significance-of-androgen-receptor-splice-variant-7-in-patients-with-metastatic-castration-resistant-prostate-cancer-the-prophecy-study
#11
Luc Dirix
No abstract text is available yet for this article.
July 2, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31265357/reply-to-l-dirix-b-de-laere-et-al-and-a-sharp-et-al
#12
Andrew J Armstrong, Susan Halabi, Jun Luo, David M Nanus, Howard I Scher, Emmanuel S Antonarakis, Daniel J George
No abstract text is available yet for this article.
July 2, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31260645/reply-to-j-b-aragon-ching
#13
Seth A Rosenthal, Chen Hu, Oliver Sartor, Felix Y Feng, Howard M Sandler
No abstract text is available yet for this article.
July 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31260644/mortality-after-breast-cancer-among-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-study
#14
Chaya S Moskowitz, Joanne F Chou, Joseph P Neglia, Ann H Partridge, Rebecca M Howell, Lisa R Diller, Danielle Novetsky Friedman, Dana Barnea, Lindsay M Morton, Lucie M Turcotte, Michael A Arnold, Wendy M Leisenring, Gregory T Armstrong, Leslie L Robison, Kevin C Oeffinger, Tara O Henderson
PURPOSE: Female survivors of childhood cancer have a high risk of subsequent breast cancer. We describe the ensuing risk for mortality and additional breast cancers. PATIENTS AND METHODS: Female participants in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of cancer diagnosed between 1970 and 1986 before age 21 years, and subsequently diagnosed with breast cancer (n = 274; median age at breast cancer diagnosis, 38 years; range, 20 to 58 years) were matched to a control group (n = 1,095) with de novo breast cancer...
July 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31260643/adjuvant-chemotherapy-for-high-risk-localized-prostate-cancer-time-for-change-or-need-more-time-to-change
#15
Jeanny B Aragon-Ching
No abstract text is available yet for this article.
July 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31260642/promoting-breast-cancer-surveillance-the-empower-study-a-randomized-clinical-trial-in-the-childhood-cancer-survivor-study
#16
Kevin C Oeffinger, Jennifer S Ford, Chaya S Moskowitz, Joanne F Chou, Tara O Henderson, Melissa M Hudson, Lisa Diller, Aaron McDonald, James Ford, Nidha Z Mubdi, Dayton Rinehart, Christopher Vukadinovich, Todd M Gibson, Nassim Anderson, Elena B Elkin, Kathleen Garrett, Margaret Rebull, Wendy Leisenring, Leslie L Robison, Gregory T Armstrong
PURPOSE: The aim of the current study was to increase the uptake of screening mammography among high-risk women who were treated for a childhood cancer with chest radiotherapy. PATIENTS AND METHODS: Two hundred four female survivors in the Childhood Cancer Survivor Study who were treated with chest radiotherapy with 20 Gy or greater, age 25 to 50 years, and without breast imaging in the past 24 months were randomly assigned 2:1 to receive a mailed informational packet followed by a tailored telephone-delivered brief motivational interview (intervention) versus an attention control...
July 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31260641/immunotherapy-for-urothelial-cancer-where-are-the-randomized-trials
#17
Francisco E Vera-Badillo, Ian F Tannock, Christopher M Booth
No abstract text is available yet for this article.
July 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31251694/cost-effectiveness-of-interval-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-in-stage-iii-ovarian-cancer-on-the-basis-of-a-randomized-phase-iii-trial
#18
Simone N Koole, Christiaan van Lieshout, Willemien J van Driel, Evi van Schagen, Karolina Sikorska, Jacobien M Kieffer, Jules H Schagen van Leeuwen, Henk W R Schreuder, Ralph H Hermans, Ignace H de Hingh, Jacobus van der Velden, Henriette J Arts, Leon F A G Massuger, Arend G Aalbers, Victor J Verwaal, Koen K Van de Vijver, Neil K Aaronson, Harm van Tinteren, Gabe S Sonke, Wim H van Harten, Valesca P Retèl
PURPOSE: In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and overall survival in patients with stage III ovarian cancer. We studied the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer. PATIENTS AND METHODS: We constructed a Markov health-state transition model to measure costs and clinical outcomes...
June 28, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31251693/reply-to-e-hindi%C3%A3-et-al
#19
Roisin M Connolly, Chiung-Yu Huang, Vered Stearns, Richard L Wahl
No abstract text is available yet for this article.
June 28, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31251692/interim-18-f-fluorodeoxyglucose-positron-emission-tomography-during-neoadjuvant-therapy-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#20
Elif Hindié, David Groheux
No abstract text is available yet for this article.
June 28, 2019: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"